Primary Dysmenorrhea - Pipeline Review, H2 2014

Date: July 31, 2014
Pages: 37
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PCA1C4C954AEN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Primary Dysmenorrhea - Pipeline Review, H2 2014’, provides an overview of the Primary Dysmenorrhea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Dysmenorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Primary Dysmenorrhea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Primary Dysmenorrhea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Primary Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Primary Dysmenorrhea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Primary Dysmenorrhea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Primary Dysmenorrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Primary Dysmenorrhea Overview
Therapeutics Development
Pipeline Products for Primary Dysmenorrhea - Overview
Pipeline Products for Primary Dysmenorrhea - Comparative Analysis
Primary Dysmenorrhea - Therapeutics under Development by Companies
Primary Dysmenorrhea - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Primary Dysmenorrhea - Products under Development by Companies
Primary Dysmenorrhea - Companies Involved in Therapeutics Development
Merck & Co., Inc.
PDC Biotech GmbH
Jiangsu Kanion Pharmaceutical Co., Ltd.
Primary Dysmenorrhea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
KYG-0395 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etonogestrel Vaginal Ring - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDC-31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptidometics - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDC-41 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Primary Dysmenorrhea - Recent Pipeline Updates
Primary Dysmenorrhea - Dormant Projects
Primary Dysmenorrhea - Product Development Milestones
Featured News & Press Releases
Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor
Nov 01, 2012: Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related To Vioxx
Nov 15, 2010: PDC Biotech announces start of Phase l trial - novel peptide for treatment of preterm labour and primary dysmenorrhea
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007.
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Primary Dysmenorrhea, H2 2014
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Primary Dysmenorrhea - Pipeline by Merck & Co., Inc., H2 2014
Primary Dysmenorrhea - Pipeline by PDC Biotech GmbH, H2 2014
Primary Dysmenorrhea - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Primary Dysmenorrhea Therapeutics - Recent Pipeline Updates, H2 2014
Primary Dysmenorrhea - Dormant Projects, H2 2014

LIST OF FIGURES

Number of Products under Development for Primary Dysmenorrhea, H2 2014
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

COMPANIES MENTIONED

Merck & Co., Inc.
PDC Biotech GmbH
Jiangsu Kanion Pharmaceutical Co., Ltd.
Skip to top


Dysmenorrhea - Pipeline Review, H2 2014 US$ 1,600.00 Dec, 2014 · 38 pages

Ask Your Question

Primary Dysmenorrhea - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: